Edouard J. Louis
Expertise in
9
conditions

Edouard J. Louis

CHU Liège
Liege, WAL, BE 
Expertise in
9
conditions
CHU Liège
Liege, WAL, BE 

Overview

Edouard Louis practices practicing medicine in Liege, Belgium.

Louis is highly rated in 9 conditions, according to our data. Their clinical expertise encompasses Crohn's Disease, Viral Gastroenteritis, Colitis, Endoscopy, and Colonoscopy.

They are actively involved in clinical research, co-authoring 383 peer reviewed articles and participating in 11 clinical trials.

Locations

CHU Liège
Liege, WAL, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drug: Cx601
Study Phase: Phase 3
Prospective, Non-Interventional, Observational Study in Patients With IBD Receiving IV or SC Vedolizumab Therapy to Observe Route of Administration Choices and Outcomes
Prospective, Non-Interventional, Observational Study in Patients With IBD Receiving IV or SC Vedolizumab Therapy to Observe Route of Administration Choices and Outcomes
Enrollment Status: Completed
Publish Date: August 06, 2024
An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study (LOw Countries VEdolizumab in CD Study)
An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study (LOw Countries VEdolizumab in CD Study)
Enrollment Status: Completed
Publish Date: June 23, 2023
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 4
Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis- In-TARGET
Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis- In-TARGET
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drug: Golimumab
Study Phase: Phase 4
Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab
Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab
Enrollment Status: Unknown
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drug: Adalimumab
Study Phase: Phase 4
Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Chrohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab
Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Chrohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab
Enrollment Status: Completed
Publish Date: January 05, 2023
Intervention Type: Drug
ENTYVIO® Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study
ENTYVIO® Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study
Enrollment Status: Completed
Publish Date: October 21, 2022
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy
Enrollment Status: Completed
Publish Date: August 03, 2022
Intervention Type: Drug
Study Drugs: Infliximab, Azathioprine, Mercaptopurine, Methotrexate
Study Phase: Phase 4
Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores
Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Drug: 5-HTP
Study Phase: Phase 2
An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Ulcerative Colitis: the LOVE-UC Study (LOw Countries VEdolizumab in UC Study)
An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Ulcerative Colitis: the LOVE-UC Study (LOw Countries VEdolizumab in UC Study)
Enrollment Status: Completed
Publish Date: October 08, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 9 Less Clinical Trials

383 Total Publications

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.
Exome sequencing directly implicates 68 genes in inflammatory bowel disease.
Journal: medRxiv : the preprint server for health sciences
Published: May 25, 2026

Frequently Asked Questions about Edouard J. Louis

Is Edouard J. Louis a top-rated expert for Crohn's Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Edouard J. Louis is classified as an Elite expert for Crohn's Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Edouard J. Louis participate in research or clinical trials?

Yes. Edouard J. Louis has published 383 articles and abstracts on conditions like Crohn's Disease. You can view a list of Edouard J. Louis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Louis's expertise for a condition
ConditionClose
View All 27 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile